Verastem Oncology NDAs Avutometinib for Ovarian Cancer
Verastem Oncology has completed its New Drug Application (NDA) to the U.S. FDA for a combination therapy targeting recurrent...
Synedgen Gets $2.2M for Radiation Countermeasure
Synedgen, Inc., a biotechnology company specializing in gastrointestinal disease treatment, has secured a $2.2 million contract from the Joint...
Lucent Diagnostics’ New Blood Test for Early Alzheimer’s Diagnosis
Lucent Diagnostics has launched LucentAD Complete, a novel multi-marker blood test designed to enhance the detection of Alzheimer’s Disease...
Dynamx Bioadaptor: Superior Results in Complex Coronary Cases
Elixir Medical, a company dedicated to developing innovative treatments for cardiovascular diseases, has released promising data from its INFINITY-SWEDEHEART...
Nalmefene and Naloxone for Fentanyl-Induced Respiratory Depression
A recent study published in The Journal of Clinical Pharmacology reveals that intramuscular nalmefene effectively reverses fentanyl-induced respiratory depression....
Early TAVR Superiority in Asymptomatic Severe Aortic Stenosis
The EARLY TAVR Trial, a groundbreaking study, evaluated the optimal approach to treating asymptomatic severe aortic stenosis (AS). It...
Organon Completes Acquisition of Dermavant
Organon, a global healthcare company focused on women’s health, has finalized its acquisition of Dermavant Sciences Ltd. from Roivant....
Boomi, Base Life Science Partner to Boost Digital Transformation
Boomi, a leader in intelligent integration and automation, has partnered with BASE Life Science, an Infosys company specializing in...
Aditxt Finalizes Evofem Merger Investment
Aditxt, Inc., a company focused on driving health innovations, has reached a significant milestone in acquiring Evofem Biosciences, Inc.,...
Leo Pharma Presents Long-Term Adbry® Trial Results at Fall Clinical 2024
LEO Pharma Inc., a leader in medical dermatology, announced the final results of ECZTEND, a five-year study on Adbry®...